Consensus guidelines for the design and implementation of clinical trials in ALS

Journal of the Neurological Sciences

Volumn 169, Issue 1-2, 1999, Pages 2-12

  Miller, Robert G ^a   Munsat, Theodore L ^b   Swash, Michael ^c   Brooks, Benjamin R ^d  

^a Chmn Clin Trials Consortium R   (United States)

^b Chmn WFN Res Committees Dept N   (United States)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d University W Madison   (United States)

Author keywords

ALS; Chairman WFN Research Committees; Clinical trials; Conference organizer; Guidelines; Motor neuron disease; Theodore H. Munsat; Therapeutic trials

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL RESEARCH; HUMAN; MEDICAL RESEARCH; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BIOMEDICAL AND BEHAVIORAL RESEARCH; WORLD FEDERATION OF NEUROLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; HUMANS; QUALITY OF LIFE;

EID: 0032716522     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00209-9     Document Type: Article

References (26)

1. World Federation of Neurology (WFN) Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House Guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House 'Therapeutic Trials in ALS' Workshop Contributors. J Neurol Sci 1995;129:1-10.
2. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in ALS. New Eng J Med. 330:1994;585-591.
3. Lacomblez L., Bensimon G., Leigh P.N., et al. A controlled trial of Riluzole in ALS. Lancet. 347:1996;1425-1431.
4. ALS CNTF Treatment Study Group. A double-blind, placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor in ALS. Neurology 1996;46:1244-9.
5. Lai E.C., Felice K.J., Festoff B.W., et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. The North American ALS/IGF-1 Study Group. Neurology. 49:1997;1621-1630.
6. Miller R.G., Petajan J., Bryan W.W., et al. A placebo-controlled trial of recombinant human ciliary neurotrophic factor in ALS. Ann Neurol. 39:1996;256-260.
7. Miller R.G., Moore D., Young L.A., et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 47:1996;1383-1388.
8. Ross M.A., Miller R.G., Berchert L., Parry G., Barohn R.J., et al. Toward earlier diagnosis of ALS: revised criteria. Neurology. 50:1998;768-772.
9. Schulz K.F. The quest for unbiased research: randomized clinical trials and the consort reporting guidelines. Ann. Neurol. 41:1997;569-573.
10. Tandan R., Bradley W.G. ALS. 1: clinical features, pathology and ethical issues in management. Ann. Neurol. 18:1985;271-280.
11. Kondo K., Hemmi I. Clinical statistics in 515 fatal cases of motor neuron disease. Neuroepidemiology. 3:1984;129-148.
12. Stambler N., Charatan M., Cedarbaum J.M. The ALS CNTF Study Group. Prognostic indicators of survival in ALS. Neurology. 50:1998;66-72.
13. Gubbay S.S., Kahan E., Zilber N., et al. ALS a study of its presentation and prognosis. J. Neurol. Sci. 232:1985;295-300.
14. Ringel S.P., Murphy J.R., Alderson M.K., et al. The natural history of ALS. Neurology. 43:1993;1316-1322.
15. Haverkamp L.J., Appel V., Appel S.H. Natural history of ALS in a database population; validation of a scoring system and a model for survival prediction. Brain. 118:1995;707-719.
16. Mortara P., Chio A., Rosso M.G., Leone M., Shciffer D. Motor neuron disease in the province of Turin Italy 1966-1980: survival analysis in an unselected population. J. Neurol. Sci. 66:1984;165-173.
17. Rosen A.D. ALS: clinical features and prognosis. Arch Neurol. 35:1978;638-642.
18. Caroscio J.T., Mulvihill M.N., Sterling R., Abrams B. ALS: its natural history. Neurol. Clin. 5:1987;1-8.
19. Preux P-M., Couratier P.H., Boutros-Toni F. Survival prediction in sporadic ALS. Neuroepidemiology. 15:1996;153-160.
20. Smith R.A., Melmed S., Sherman B., Frane J., Munsat T.L., Festoff B.W. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle and Nerve. 16:1993;624-633.
21. Armon C, Moses D. Linear estimates of rates of progression as predictors of survival in patients with A.L.S. enrolling into clinical trials. Presented at the 8th International Symposium on ALS/MND in Glasgow, Scotland, November 3-5, 1997.
22. Brinkmann J.R., Andres P., Mendoza M., Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J. Neurol. Sci. 147:1997;97-111.
23. Hoagland R.J., Mendoza M., Armon C., Barohn R.C., Bryan W.W., Goodpasture J.C., Miller R.G., Parry G.J., Petajan J.H., Ross M.A. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group. Muscle and Nerve. 20:1997;691-695.
24. Andres P.L., Finison L.J., Conlon T., Thibodeau L.M., Munsat T.L. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology. 38:(3):1988;405-408.
25. National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehab 1996;77:2351-5.
26. Miller RG, Rosenberg JA, Gelinas DF et al. and the ALS Practice Parameters Task Force. Practice Parameter. The care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the Quality Standards Subcommittee of the AAN. Neurology 52(7):1311-23.